Results 61 to 70 of about 249,154 (329)

Optimal management of infrainguinal arterial occlusive disease

open access: yesVascular Health and Risk Management, 2014
David J Pennywell, Tze-Woei Tan, Wayne W Zhang Division of Vascular and Endovascular Surgery, Louisiana State University Health Shreveport, Shreveport, LA, USA Abstract: Peripheral arterial occlusive disease is becoming a major health problem in Western
Pennywell DJ, Tan TW, Zhang WW
doaj  

Regulation of Neuroinflammation by Microglial DUBA‐IRAK1‐IKKβ Signaling Loop

open access: yesAdvanced Science, EarlyView.
The protein levels of deubiquitinating enzyme A (DUBA) are rapidly upregulated in microglia after activation of Toll‐like receptor 4 (TLR4). In turn, DUBA potentiates TLR4‐induced proinflammatory signal transduction in microglia by stabilizing interleukin‐1 receptor activated kinase 1 (IRAK1) through K48 deubiquitination.
Zhenhu Zhu   +22 more
wiley   +1 more source

PERIPHERAL ARTERIAL OCCLUSIVE DISEASE AND VARICOSE VEINS IN DIABETIC PATIENTS

open access: yesZdravniški Vestnik, 2004
Background. Diabetes mellitus is an independent risk factor which increase cardiovascular morbidity and mortality by 1.5–3 times. The aim of this study was to determine the difference in the frequency of peripheral arterial occlusive disease ...
Blaž Mlačak   +3 more
doaj  

Occlusive coral reef aortic plaque treated with intravascular lithotripsy and kissing iliac stents

open access: yesAnnals of Vascular Surgery - Brief Reports and Innovations
Aortoiliac occlusive disease is a common cause of claudication symptoms. When complicated by extensive calcification, successful angioplasty and resolution of symptoms may be difficult to achieve.
Jacob Ghahremani   +4 more
doaj   +1 more source

A Redox‐Active and Electroactive Hydrogel Enabled by an Integrated PEDOT@PMOF Nanofiller for Post‐Infarct Myocardial Repair

open access: yesAdvanced Science, EarlyView.
An integrated nanoparticle PEDOT@PMOF is constructed as a redox‐active nanozyme and electroactive nanofiller in a cell‐affinity hydrogel platform for acute MI treatment. It is demonstrated that MOF‐based nanozymes have good catalytic ability, and the incorporation of PEDOT increases the conductivity.
Shuyi He   +6 more
wiley   +1 more source

ENDOVASCULAR TREATMENT OF CHRONIC VENOUS OCCLUSIVE DISEASE — SPECIFICATIONS OF ENDOPROSTHESES AND COMPARISON OF RESULTS

open access: yesAngiologia e Cirurgia Vascular, 2019
Introduction: Chronic occlusive venous disease manifests mainly at the level of the iliofemoral vein, and its treatment has been revolutionized by the emergence of endovascular techniques.
Daniela Bento   +3 more
doaj   +1 more source

FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine

open access: yesAdvanced Science, EarlyView.
This study identifies flavin‐containing monooxygenase 2 (FMO2) as a novel proangiogenic regulator in endothelial cells. Targeted FMO2 ablation impairs vessel sprouting, whereas its compensation potently enhances angiogenesis. Metabolomics and single‐cell sequencing reveal that FMO2 drives vascular growth via the N‐acetylornithine/ATF3/NOTCH1 axis ...
Jingyi Wang   +15 more
wiley   +1 more source

Procyanidin B3 and Its Derivatives Alleviate Neuronal Injury by Targeting G3BP1 for Ischemic Stroke Therapy

open access: yesAdvanced Science, EarlyView.
Ischemic stroke is a serious disease with high rates of mortality and disability, but there is a lack of novel therapeutic targets and agents for it. Now it is shown that Ras GTPase‐activating protein SH3 domain‐binding protein 1 (G3BP1) has the potential to serve as a therapeutic target for ischemic stroke.
Heyanhao Zhang   +10 more
wiley   +1 more source

Incisional Hernias after Vascular Surgery for Aortoiliac Aneurysm and Aortoiliac Occlusive Arterial Disease: Has Prophylactic Mesh Changed This Scenario? [PDF]

open access: yesAorta (Stamford), 2023
Piltcher-da-Silva R   +10 more
europepmc   +1 more source

An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin

open access: yesAdvanced Science, EarlyView.
By simply conjugating thrombin's active‐site inhibitor, dabigatran, with an exosite inhibitor, aptamer HD1, the resulting EXosite‐ACTive site (EXACT) inhibitors show two orders of magnitude higher potency and selectivity via synergistic binding, while maintaining the aptamer's antidote‐reversible trait, yielding a potential substitute for the animal ...
Haixiang Yu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy